Alnylam Pharmaceuticals Announces Board Changes, Appoints Stuart Arbuckle as New Director

Alnylam Pharmaceuticals announced the departure of Mike Bonney and Carolyn Bertozzi from its Board of Directors, and the appointment of Stuart Arbuckle as a new independent director. Bonney served as Board Chair from 2015 to 2021 and as Executive Chair from 2021 to 2023, while Bertozzi joined the Board in 2023 and served on the Nominating and Corporate and Science and Technology Committees. Arbuckle brings extensive experience in biopharmaceutical commercialization and leadership from companies such as GSK, Amgen, and Vertex.